AN2 Therapeutics (ANTX) Analyst & Key Data

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

5

Hold

3

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score3.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$5.41

Median Target+66.36%

$9.00

Potential upside vs current price

DCF Value-89.03%

$0.59

Potential downside vs current price

Current Stock Price

$5.41

Median Target+66.36%

$9.00

Potential upside vs current price

DCF Value-89.03%

$0.59

Potential downside vs current price

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

5

Hold

3

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score3.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$5.41

Median Target+66.36%

$9.00

Potential upside vs current price

DCF Value-89.03%

$0.59

Potential downside vs current price

Current Stock Price

$5.41

Median Target+66.36%

$9.00

Potential upside vs current price

DCF Value-89.03%

$0.59

Potential downside vs current price

AN2 Therapeutics, Inc.